Challenges for improving medication adherence

JAMA

Volumn 296, Issue 21, 2006, Pages 2614-2616

  Simpson, Ross J ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYPOCHOLESTEROLEMIC AGENT;

EDITORIAL; HEALTH CARE SYSTEM; HUMAN; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RISK FACTOR;

EID: 33845507808     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.21.jed60074     Document Type: Editorial

References (18)

1. Pearson T, Kopin L. Bridging the treatment gap: improving compliance with lipid-modifying agents and therapeutic lifestyle changes. Prev Cardiol. 2003;6:204-211.
2. O'Connor PJ. Improving medication adherence. Arch Intern Med. 2006;166:1802-1804.
3. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomized, controlled clinical trial. Lancet. 2005;366:2005-2011.
4. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15. doi:10.1136/bmj.38875.675486.
5. Di Martino M, Degli Esposito L, Ruffo P, et al. Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. Eur J Clin Pharmacol. 2005;61:225-230.
6. Foley KA, Denke MA, Kamal-Bahl S, et al. The impact of physician attitudes and beliefs on treatment decisions in lipid therapy in high risk patients. Med Care. 2006;44:421-428.
7. Roumie CL, Elasy TA, Greevy R, et al. Improving blood pressure control through provider education, provider alerts, and patient education. Ann Intern Med. 2006; 145:165-175.
8. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment. JAMA. 2002;288:2880-2883.
9. Petrilla AA, Benner JS, Battleman DS, Tierce JC, Hazard EH. Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medications. Int J Clin Pract. 2005;59:1441-1451.
10. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353: 487-497.
11. Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm. 2003;60:657-665.
12. Ali F, Laurin MY, Lariviere C, Tremblay D, Cloutier D. The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels. Can J Clin Pharmacol. 2003;10:101-106.
13. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med. 2002;162: 1149-1155.
14. Tsuyuki RT, Olson KL, Dubyk AM, Schindel TJ, Johnson JA. Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular risk intervention by pharmacists (SCRIP-plus). Am J Med. 2004;116:130-133.
15. Lee SSCL, Cheung PYP, Chow MSSC. Benefits of individualized counseling by the pharmacist on the treatment outcomes of hyperlipidemia in Hong Kong. J Clin Pharmacol. 2004;44:632-639.
16. Rehring TF, Stolcpart RS, Sandhoff BG, Merenich JA, Hollis HW Jr. Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease. J Vasc Surg. 2006;43:1205-1210.
17. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2563-2571.
18. Delgado-Rodriguez M, Llorca J. Bias. J Epidemiol Community Health. 2004; 58:635-641.